Siglecs and their ligands are expressed by many tumors, and can serve to down-regulate immune response. REVIEW article: “The intriguing roles of Siglec family members in the tumor microenvironment” Kui-Ying Jiang, Ling Wang, et al. (2022) Biomarker Research 10: 22 PMID: 35418152 “Molecular Mechanism of Tumor Cell Immune Escape Mediated by CD24/Siglec-10” Shan-Shan Yin, Feng-Hou Gao […]

CF33-hNIS, a modified vaccinia (small pox) virus will be tested by IV or Intratumoral injection, with or without PD-1 inhibitor, pembrolizumab in patients with advanced or metastaic solid tumors. Link to Medical News Today Article Link to Clinical Trial Link to a Background article Ancell human PD-1 related Research Products CD279(PD-1) CD274 (PD-L1) CD273 (PD-L2)

“Development of a flow cytometry-based potency assay for prediction of cytokine storms induced by biosimilar monoclonal antibodies” Natasha Helleberg Madsen, Monika Gad, Jesper Larsen. (Feb 5, 2022) J Immunol Methods 502: 113231. https://doi.org/10.10 PBMC were stimulated with immobilized ANC28.1, CD28.1 and muromonab CD3. Assessed Cytokines and levels of Activation molecules by flow could determine the

“Increase in SARS-CoV-2 RBD-specific IgA and IgG Antibodies in Breast Milk from Lactating Women Following the COVID-19 Booster Vaccination” Andrea M Henle MedRxiv (Feb 24, 2022 Pre print) doi: https://doi.org/10.1101/2022.02.23.22271414 Related Ancell products: anti-human IgA monoclonal antibody anti-human IgG monoclonal antibody Recombinant SARS-CO-V2-RBD-His protein #581-820 (Inquire)

A University of WI Madison research group used Ancell antibodies to analyze exosomes involved in the induction of tolerance to non-inherited maternal antigens(NIMA). This could have implications for allogeneic graft tolerance./ “Cross-Decoration of Dendritic Cells by Non-Inherited Maternal Antigen-Containing Extracellular Vesicles: Potential Mechanism for PD-L1-Based Tolerance in Cord Blood and Organ Transplantation”Diego A. Lema, A

In a Mayo Clinic study, the blood from 19 T-ALL patients were compared to 24 normal samples using a flow cytometric panel. While the normal samples all showed a “characteristic and reproducible” pattern of cellsurface expressed CD3 and TRBC1 positivity, the leukemic samples were either almost entirely TRCB1 positive or almost entirely negative, indicating T

Ancell anti-CD26 and anti-CD36 biotinylated antibodies used to capture HIV Virions from CSF of patients undergoing ARV treatment. The markers on sorted virions correlate with host cellular origin. “T cell derived HIV-1 is present in the CSF in the face of suppressive anti-retroviral therapy” G Lustig, A Sigal, et al. (Sep 2021) PLoS Pathog 17(9):